1. Home
  2. TNGX vs DENN Comparison

TNGX vs DENN Comparison

Compare TNGX & DENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • DENN
  • Stock Information
  • Founded
  • TNGX 2014
  • DENN 1953
  • Country
  • TNGX United States
  • DENN United States
  • Employees
  • TNGX N/A
  • DENN N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • DENN Restaurants
  • Sector
  • TNGX Health Care
  • DENN Consumer Discretionary
  • Exchange
  • TNGX Nasdaq
  • DENN Nasdaq
  • Market Cap
  • TNGX 351.2M
  • DENN 203.4M
  • IPO Year
  • TNGX N/A
  • DENN 1989
  • Fundamental
  • Price
  • TNGX $5.02
  • DENN $4.10
  • Analyst Decision
  • TNGX Strong Buy
  • DENN Strong Buy
  • Analyst Count
  • TNGX 6
  • DENN 6
  • Target Price
  • TNGX $12.20
  • DENN $7.46
  • AVG Volume (30 Days)
  • TNGX 4.0M
  • DENN 512.9K
  • Earning Date
  • TNGX 08-06-2025
  • DENN 07-29-2025
  • Dividend Yield
  • TNGX N/A
  • DENN N/A
  • EPS Growth
  • TNGX N/A
  • DENN N/A
  • EPS
  • TNGX N/A
  • DENN 0.33
  • Revenue
  • TNGX $40,990,000.00
  • DENN $453,997,000.00
  • Revenue This Year
  • TNGX N/A
  • DENN $7.51
  • Revenue Next Year
  • TNGX N/A
  • DENN $1.98
  • P/E Ratio
  • TNGX N/A
  • DENN $12.50
  • Revenue Growth
  • TNGX 10.09
  • DENN N/A
  • 52 Week Low
  • TNGX $1.03
  • DENN $2.85
  • 52 Week High
  • TNGX $12.02
  • DENN $7.73
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 69.44
  • DENN 50.11
  • Support Level
  • TNGX $4.70
  • DENN $3.94
  • Resistance Level
  • TNGX $5.63
  • DENN $4.33
  • Average True Range (ATR)
  • TNGX 0.60
  • DENN 0.18
  • MACD
  • TNGX -0.01
  • DENN -0.01
  • Stochastic Oscillator
  • TNGX 65.38
  • DENN 32.56

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

About DENN Denny's Corporation

Denny's Corp is one of America's franchised full-service restaurant chains based on the number of restaurants. The company owns and operates the Denny's brand and the Keke's Breakfast Cafe brand. It provides Pancakes, Appetizers & Soups, Sandwiches & Salads, Breakfast Melts, Omelets, and others. The company generates its revenue from two sources: the sale of food and beverages and the collection of royalties, advertising revenue, initial and other fees, including occupancy revenue, from restaurants operated by their franchisees.

Share on Social Networks: